• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Progyny Expands its Leadership Team

    1/11/24 9:01:00 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care
    Get the next $PGNY alert in real time by email

    NEW YORK, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Progyny (NASDAQ:PGNY), a transformative fertility, family building, and women's health benefits solution, today announced two newly created roles with the appointment of Katie Higgins as Chief Commercial Officer and Steven Leist as Chief Technology Officer.

    "We are excited to expand our executive team and welcome Katie and Steven to Progyny. Their expertise will further advance our growth and momentum in the fertility, family building, and women's health benefits space," said Pete Anevski, Progyny's CEO.

    With over 25 years of healthcare experience, Katie Higgins will be overseeing the teams that drive revenue, business growth, and client success. Prior to Progyny, Higgins was the Chief Revenue Officer at Crossover Health, a national medical group providing an innovative model of advanced primary care to the country's largest self-insured employers, where she spearheaded the company's go-to-market strategy. Prior to her tenure at Crossover, Katie spent three impactful years at Optum, where she led teams in crafting innovative collaborations with health systems, and 20 years at the Advisory Board Company, where she played a pivotal role in leading strategic account teams that served as thought partners to some of the nation's largest health systems. Katie holds a Bachelor of Arts in Political Science from Davidson College in North Carolina.

    "I am thrilled to be joining Progyny at this exciting time in our industry's evolution," said Higgins. "Progyny has demonstrated unmatched excellence in every metric we aspire to achieve in healthcare – access, cost, clinical outcomes, patient and provider satisfaction. Joining this team represents a unique opportunity to contribute to its continued growth and innovation in reproductive and women's health."

    Steven brings over 28 years of experience as a technology leader and will be overseeing the engineering, information technology, and cyber security functions. Prior to Progyny, Steven served as Vice President, Customer Technology at American Airlines, where he managed a global team of over 1,300 professionals, responsible for technology solutions that benefit both American Airlines' customers and the dedicated team members who support them. Steven's background also includes leadership roles in managing American's global infrastructure and operations footprint, revenue and planning technology, and helping modernize airport operations systems during his tenure. Steven holds a Bachelor of Science in Computer Engineering from Texas A&M University.

    "As someone who has personally navigated the challenges of building their family, I'm inspired by Progyny's mission and wish my family had Progyny's services at the time," said Leist. "The Progyny culture is invigorating and I'm eager to join the team and help deliver technology solutions that support the company's goals."

    For more information visit www.progyny.com.

    About Progyny

    Progyny (NASDAQ:PGNY) is a transformative fertility, family building and women's health benefits solution, trusted by the nation's leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive and intentionally designed solutions simultaneously benefit employers, patients and physicians. 

    Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs. 

    Headquartered in New York City, Progyny has been recognized for its leadership and growth by CNBC Disruptor 50, Modern Healthcare's Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times, INC. 5000, Inc Power Partners and Crain's Fast 50 for NYC. For more information, visit www.progyny.com.

    For Further Information, Please Contact:

    Investors:

    James Hart

    [email protected]

    Media:

    Alexis Ford

    [email protected]



    Primary Logo

    Get the next $PGNY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PGNY

    DatePrice TargetRatingAnalyst
    12/2/2024$17.00Overweight → Neutral
    Analyst
    11/13/2024$26.00 → $19.00Buy → Hold
    Truist
    9/19/2024Mkt Outperform → Mkt Perform
    JMP Securities
    8/7/2024$37.00 → $24.00Buy → Hold
    Canaccord Genuity
    8/7/2024$31.00 → $25.00Outperform → Market Perform
    Leerink Partners
    8/7/2024Buy → Neutral
    BTIG Research
    7/16/2024$36.00Mkt Outperform
    JMP Securities
    5/10/2024Overweight → Sector Weight
    KeyBanc Capital Markets
    More analyst ratings

    $PGNY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Progyny downgraded by Analyst with a new price target

      Analyst downgraded Progyny from Overweight to Neutral and set a new price target of $17.00

      12/2/24 10:07:08 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Progyny downgraded by Truist with a new price target

      Truist downgraded Progyny from Buy to Hold and set a new price target of $19.00 from $26.00 previously

      11/13/24 8:20:07 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Progyny downgraded by JMP Securities

      JMP Securities downgraded Progyny from Mkt Outperform to Mkt Perform

      9/19/24 7:51:03 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care

    $PGNY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Executive Chairman Schlanger David J bought $2,202,330 worth of shares (150,000 units at $14.68), increasing direct ownership by 192% to 228,269 units (SEC Form 4)

      4 - Progyny, Inc. (0001551306) (Issuer)

      12/26/24 5:35:03 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • CHIEF EXECUTIVE OFFICER Anevski Peter bought $3,034,084 worth of shares (209,500 units at $14.48), increasing direct ownership by 90% to 441,463 units (SEC Form 4)

      4 - Progyny, Inc. (0001551306) (Issuer)

      12/26/24 5:31:32 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care